American Gene Technologies
15010 Broschart Rd., Suite 110
21 articles with American Gene Technologies
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
HIV Cure Program Releases Initial Clinical Trial Data
American Gene Technologies announced that the Data and Safety Monitoring Board voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the treatment.
American Gene Technologies Announces First Trial Participant Enrolled in Phase 1 Study of AGT103-T Against HIV
American Gene Technologies (AGT) announced today that the first trial participant was enrolled in the Phase 1 trial of AGT103-T , a new cell and gene therapy for HIV disease. The first trial participant underwent leukapheresis, a procedure for obtaining concentrated white blood cells, which will be used for manufacturing the AGT103-T cell product. After manufacturing and required safety testing, the product will be infused back into the tr
American Gene Technologies to Present at 2020 Virtual Cell & Gene Meeting on the Mesa
American Gene Technologies (AGT) a cutting-edge cell and gene therapy company in Rockville, Maryland announced today that CEO Jeff Galvin will present at the annual Cell & Gene Meeting on the Mesa. The meeting will be held virtually October 12-16. Galvin’s presentation will highlight the company's technology, including AGT103-T, a therapeutic intended to cure HIV, which is scheduled to begin Phase 1 clinical trials this month. Specifics
Clinical Catch-Up: August 10-14
8/17/2020It was a very busy week for clinical trial updates. Here’s a look.
American Gene Technologies (AGT), based in Rockville, Maryland, received the go-ahead from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial of AGT103-T, a gene therapy, to eliminate HIV from infected individuals.
FDA Approves American Gene Technologies (AGT) to Move Forward with Phase 1 Clinical Trial of HIV Cure Program
American Gene Technologies (AGT) announced today approval by the FDA (Food and Drug Administration) to begin Phase 1, the first human clinical trial for AGT’s lead HIV program . AGT will conduct its Phase 1 study at clinical sites in the Baltimore/D.C. area, and has named Washington Health Institute, University of Maryland, Institute of Human Virology and Georgetown University as its initial trial sites. These sites are expected to
Molecular Therapy Peer-Reviewed Article by AGT and NIAID Outlines Preclinical Data, Shows Potential for HIV Functional Cure
American Gene Technologies (AGT), an internationally recognized advanced gene and cell therapy company in Rockville, MD, today announced a coauthored article by scientists from AGT and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), regarding AGT’s promising cell and gene therapy for HIV. Through a collaboration agreement initiated in 2019 between AGT and NIAID, gover
American Gene Technologies (AGT) Moves HQ to New Facility, Expands Lab Space for HIV and Cancer Cure ResearchAcross From National Cancer Institute Campus
American Gene Technologies (AGT), an internationally recognized leading gene and cell therapy company in Rockville, Maryland, today announced it has leased a spacious, modern facility in the Maryland life sciences corridor, across from National Cancer Institute and Johns Hopkins Shady Grove Campus.
Jeff Galvin, CEO of American Gene Technologies (AGT), had 30 years of business and entrepreneurial experience in Silicon Valley during the formative years of the personal computing and internet era.
American Gene Technologies to Present at 2020 Inborn Errors of Metabolism Drug Development Summit in Boston
American Gene Technologies (AGT), a leading gene and cell therapy company in Rockville, Maryland, is pleased to announce its Chief Science Officer C. David Pauza, Ph.D will present at the Inborn Errors of Metabolism Drug Development Summit in Boston, MA on March 11, 2020.
American Gene Technologies To Attend J.P. Morgan Healthcare Conference 2020
American Gene Technologies announced that its Chief Executive Officer, Jeff Galvin, will attend the 38th annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis between January 12-16 in San Francisco, California.
American Gene Technologies Hosts Celebration Event For Its First IND Submission (For HIV) To The Food and Drug Administration (FDA)
American Gene Technologies announced it will host a red carpet event tonight to celebrate a significant milestone in the company’s 11-year history of scientific research in cell and gene therapy: AGT successfully submitted its Investigational New Drug application to the Food & Drug Administration to begin a Phase 1 clinical trial for its genetically modified autologous cell therapy for HIV.
GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV
GeoVax Labs, Inc. announced its participation in a planned clinical trial led by researchers at American Gene Technologies, to develop a therapy aimed at eliminating HIV from infected people..
American Gene Technologies Announces Progress Toward Phase I Clinical Trial of AGT103-T for HIV Functional Cure
Completes process development for the AGT103-T automated cell manufacturing protocol.
American Gene Technologies Receives U.S. Patent on Novel Immuno-Oncology Methods of Treating Cancer Through Activation of Gamma Delta T Cells
Patent encompasses AGT’s advanced gene and cell therapy strategy for oncology.
American Gene Technologies International Appoints Julia R. Brown To Its Board Of Directors
American Gene Technologies International CEO To Present At The 2017 BIO International Convention
American Gene Technologies International Announces C. Neil Lyons As Chief Financial Officer
GeoVax Labs Inc. Announces Collaboration With American Gene Technologies International For HIV Functional Cure